Viewing Study NCT00071461



Ignite Creation Date: 2024-05-05 @ 11:32 AM
Last Modification Date: 2024-10-26 @ 9:09 AM
Study NCT ID: NCT00071461
Status: COMPLETED
Last Update Posted: 2012-02-24
First Post: 2003-10-23

Brief Title: Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis
Sponsor: Actelion
Organization: Actelion

Study Overview

Official Title: A Double-blind Randomized Placebo-controlled Multicenter Study to Assess the Efficacy Safety and Tolerability of Bosentan in Patients With Idiopathic Pulmonary Fibrosis Open Label Extension
Status: COMPLETED
Status Verified Date: 2012-02
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: BUILD 1
Brief Summary: Endothelin-1 ET-1 is expressed in a variety of pulmonary pathological conditions including pulmonary vascular disease and pulmonary fibrosis

Bosentan an oral dual ET-1 receptor antagonist could delay the progression of idiopathic pulmonary fibrosis IPF a condition for which no established treatment is available

The present trial investigates a possible use of bosentan which is currently approved for the treatment of symptoms of pulmonary arterial hypertension PAH WHO class III and IV to a new category of patients suffering from IPF

It was decided to offer Open Label treatment bosentan for patients willing to continue in the BUILD 1 study
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
BUILD 1 None None None